Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Herpes Simplex Virus Treatment Market

Herpes Simplex Virus Treatment Market Share

Report ID: GMI7466
Published Date: Nov 2023
Report Format: PDF

Download Free Sample

Herpes Simplex Virus Treatment Market Share

The herpes simplex virus treatment industry is characterized by diverse players competing in the healthcare industry. GlaxoSmithKline plc, Pfizer Inc, and Teva Pharmaceutical Industries Ltd account for significant market share. These prominent players thrive through a combination of strategic initiatives, investing in research and development, meeting the specific needs of patients, strategic approaches, product diversification, and regulatory compliance.

The players operating in the herpes simplex virus treatment industry is as mentioned below:

GlaxoSmithKline plc
Pfizer Inc
Teva Pharmaceutical Industries Ltd
Glenmark Pharmaceuticals Limited
Amneal Pharmaceuticals LLC
Novartis AG
Abbott Laboratories
Fresenius Kabi AG
Emcure Pharmaceuticals Ltd
Viatris Inc.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Herpes simplex virus treatment industry was valued at USD 2.6 billion in 2022 and is projected to surpass USD 3.8 billion by 2032, driven by increasing prevalence of herpes infection, rising R&D, growing government funding, and increasing healthcare expenditure.

The HSV-1 segment held a market share of 83.2% in 2022 and is projected to witness substantial gains by 2032, driven by the increasing prevalence of HSV-1 infection among the population, along with the recurrent nature of oral herpes outbreaks.

North America herpes simplex virus treatment industry held a revenue share of 56.8% in 2022 & is anticipated to grow robustly through 2032 driven by significant burden of HSV infections and advanced healthcare infrastructure in the region.

GlaxoSmithKline plc, Pfizer Inc, Teva Pharmaceutical Industries Ltd, Glenmark Pharmaceuticals Limited, Amneal Pharmaceuticals LLCare some of the major industry contenders.